Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In October 1984 I arrived at Oxford University, trailing a large steamer trunk containing a couple of changes of clothing and about five dozen textbooks. I had a freshly minted bachelor’s degree in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Chris Wedel is a fan of all things tech and gadgets. Living in rural Kansas with his wife and two young boys makes finding ways to stay online tricky — not to mention making my homestead smarter.

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The caravan members all declare that they are Hachibee, so you need to determine which one is your true target. Bloody Strings Hachibee hates the Shamisen, so whip yours out and play any of your ...

Michigan bluegrass phenom Billy Strings and his band stopped by NPR’s Tiny Desk for a performance more than a decade in the making. Backed by his band — Alex Hargreaves on fiddle, backing vocalist ...